新兴技术治疗角膜新生血管。
Emerging techniques to treat corneal neovascularisation.
机构信息
Institute of Ophthalmology, University College London, London, UK.
出版信息
Eye (Lond). 2012 Jan;26(1):2-12. doi: 10.1038/eye.2011.246. Epub 2011 Oct 7.
Abstract
Neovascularisation is a major cause of visual loss in a number of ophthalmic diseases. This review aims to outline the basic regulators of vessel growth in corneal neovascularisation. An understanding of the underlying principles of physiological and pathophysiological vascular development helps to appreciate current approaches to prevent or treat corneal neovascularisation. Options for future interventions will be discussed in the light of recent evidence provided by animal models of corneal neovascularisation.
摘要
新生血管形成是许多眼科疾病导致视力丧失的主要原因。本综述旨在概述角膜新生血管形成中血管生长的基本调节因子。了解生理性和病理性血管发育的基本原理有助于理解当前预防或治疗角膜新生血管形成的方法。根据角膜新生血管形成的动物模型提供的最新证据，讨论未来干预措施的选择。
相似文献
1
Emerging techniques to treat corneal neovascularisation.新兴技术治疗角膜新生血管。
Eye (Lond). 2012 Jan;26(1):2-12. doi: 10.1038/eye.2011.246. Epub 2011 Oct 7.
2
Corneal neovascularization: an anti-VEGF therapy review.角膜新生血管：抗血管内皮生长因子治疗综述。
Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007.
3
Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.血清滴眼剂在体外和体内拮抗贝伐单抗的抗（淋巴）血管生成作用。
Invest Ophthalmol Vis Sci. 2013 Sep 11;54(9):6133-42. doi: 10.1167/iovs.13-12460.
4
Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.在不同的角膜新生血管兔模型中结膜下注射贝伐单抗（阿瓦斯汀）对角膜新生血管的影响
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1659-65. doi: 10.1167/iovs.08-1997. Epub 2008 Nov 7.
5
[Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].[局部应用贝伐单抗和舒尼替尼诱导动物模型角膜新生血管形成的血管形态学及微血管密度变化]
Arch Soc Esp Oftalmol. 2013 Dec;88(12):473-81. doi: 10.1016/j.oftal.2013.07.007. Epub 2013 Oct 7.
6
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.局部应用贝伐单抗（阿瓦斯汀）滴眼液治疗角膜新生血管的短期和长期安全性及疗效
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82. doi: 10.1007/s00417-009-1099-1. Epub 2009 May 5.
7
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).贝伐单抗（阿瓦斯汀）对实验性角膜新生血管形成的抑制作用
Br J Ophthalmol. 2007 Jun;91(6):804-7. doi: 10.1136/bjo.2006.107912. Epub 2006 Dec 19.
8
The effect of bevacizumab on corneal neovascularization in rabbits.贝伐单抗对兔角膜新生血管形成的影响。
Korean J Ophthalmol. 2010 Aug;24(4):230-6. doi: 10.3341/kjo.2010.24.4.230. Epub 2010 Aug 3.
9
Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.结膜下注射托珠单抗与贝伐单抗治疗兔角膜新生血管的效果比较
Cornea. 2014 Oct;33(10):1088-94. doi: 10.1097/ICO.0000000000000220.
10
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).通过结膜下注射贝伐单抗（阿瓦斯汀）抑制实验性角膜新生血管形成。
Cornea. 2008 Apr;27(3):349-52. doi: 10.1097/ICO.0b013e31815cf67d.
引用本文的文献
1
A cell-permeable peptide inhibitor of p55PIK signaling alleviates suture-induced corneal neovascularization and inflammation.一种p55PIK信号通路的细胞穿透性肽抑制剂可减轻缝线诱导的角膜新生血管形成和炎症。
Heliyon. 2023 Mar 31;9(4):e14869. doi: 10.1016/j.heliyon.2023.e14869. eCollection 2023 Apr.
2
Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report.采用抗 VEGF 注射联合氩激光光凝应用治疗角膜新生血管 - 病例报告。
Rom J Ophthalmol. 2021 Jul-Sep;65(3):286-289. doi: 10.22336/rjo.2021.58.
3
Knockdown of LncRNA SNHG1 Suppresses Corneal Angiogenesis by the Regulation of miR-195-5p/VEGF-A.下调长链非编码RNA SNHG1通过调控miR-195-5p/血管内皮生长因子A抑制角膜血管生成。
J Ophthalmol. 2021 Oct 19;2021:6646512. doi: 10.1155/2021/6646512. eCollection 2021.
4
Corneal angiogenic privilege and its failure.角膜血管生成特权及其失败。
Exp Eye Res. 2021 Mar;204:108457. doi: 10.1016/j.exer.2021.108457. Epub 2021 Jan 22.
5
Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization Via Inhibition of VEGF Production.透明质酸-RGD肽包被的明胶/表没食子儿茶素-3-没食子酸酯（EGCG）纳米颗粒的局部应用通过抑制血管内皮生长因子（VEGF）的产生来抑制角膜新生血管形成。
Pharmaceutics. 2020 Apr 28;12(5):404. doi: 10.3390/pharmaceutics12050404.
6
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.SKLB1002，一种有效的 VEGF 受体 2 信号抑制剂，在体外抑制内皮细胞的血管生成功能，在体内抑制眼血管生成。
Mol Med Rep. 2020 Jun;21(6):2571-2579. doi: 10.3892/mmr.2020.11056. Epub 2020 Apr 6.
7
lncRNA MIAT suppression alleviates corneal angiogenesis through regulating miR-1246/ACE.长链非编码 RNA MIAT 的抑制作用通过调节 miR-1246/ACE 缓解角膜血管生成。
Cell Cycle. 2019 Mar-Apr;18(6-7):661-669. doi: 10.1080/15384101.2019.1578143. Epub 2019 Mar 5.
8
Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.制备含有表没食子儿茶素-3-没食子酸酯的精氨酸-甘氨酸-天冬氨酸修饰的生物聚合物纳米颗粒，用于靶向血管内皮细胞以抑制角膜新生血管形成。
Int J Nanomedicine. 2016 Dec 30;12:279-294. doi: 10.2147/IJN.S114754. eCollection 2017.
9
Anti-apoptosis effects of vascular endothelial cadherin in experimental corneal neovascularization.血管内皮钙黏蛋白在实验性角膜新生血管形成中的抗凋亡作用
Int J Ophthalmol. 2015 Dec 18;8(6):1083-8. doi: 10.3980/j.issn.2222-3959.2015.06.01. eCollection 2015.
10
Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury.基质金属蛋白酶在创伤性脑损伤发病机制中的作用
Mol Neurobiol. 2016 Nov;53(9):6106-6123. doi: 10.1007/s12035-015-9520-8. Epub 2015 Nov 5.
本文引用的文献
1
Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.结膜下注射贝伐单抗后泪液中补偿性生长因子和细胞因子反应。
Cornea. 2011 Oct;30(10):1071-7. doi: 10.1097/ICO.0b013e31820cd3f4.
2
Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable.关于抗血管生成治疗在新生血管相关性角膜疾病管理中的适应证的专家共识声明：专家圆桌会议的结果。
Br J Ophthalmol. 2012 Jan;96(1):3-9. doi: 10.1136/bjo.2011.204701. Epub 2011 Jun 28.
3
Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.联合应用结膜下和角膜内注射贝伐单抗治疗角膜新生血管。
Cornea. 2011 Oct;30(10):1110-4. doi: 10.1097/ICO.0b013e31821379aa.
4
Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.局部应用皮质类固醇抑制炎性角膜淋巴管生成。
Arch Ophthalmol. 2011 Apr;129(4):445-52. doi: 10.1001/archophthalmol.2011.42.
5
[Antiangiogenic therapy at the ocular surface: when, what and why?].[眼表的抗血管生成治疗：时机、方法及原因？]
Ophthalmologe. 2011 Mar;108(3):230-6. doi: 10.1007/s00347-010-2262-0.
6
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.血管生成素-1 抑制在抑制血管生成和肿瘤生长中的上下文相关作用：AMG 386，一种血管生成素-1/2 中和肽抗体的意义。
Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.
7
Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis.角膜新生血管是角膜移植术后移植物失败和排斥的危险因素：一项基于证据的荟萃分析。
Ophthalmology. 2010 Jul;117(7):1300-5.e7. doi: 10.1016/j.ophtha.2010.01.039. Epub 2010 Jun 3.
8
Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.在动物模型中，局部应用贝伐单抗（抗 VEGF）和舒尼替尼（抗 VEGF 和抗 PDGF）抑制角膜新生血管形成。
Am J Ophthalmol. 2010 Oct;150(4):519-528.e1. doi: 10.1016/j.ajo.2010.04.024. Epub 2010 Jun 29.
9
Ocular angiogenesis: mechanisms and recent advances in therapy.眼部血管生成：机制与治疗新进展。
Adv Clin Chem. 2010;50:103-21.
10
The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.早期和晚期贝伐单抗（阿瓦斯汀）注射抑制兔角膜缘不全的角膜新生血管和结膜化的不同作用。
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6277-85. doi: 10.1167/iovs.09-4571. Epub 2010 Apr 30.
Zotero 插件